Premium
JC virus granule cell neuronopathy and GCN–IRIS under natalizumab treatment
Author(s) -
Schippling Sven,
Kempf Christian,
Büchele Fabian,
Jelcic Ivan,
Bozinov Oliver,
Bont Adriano,
Linnebank Michael,
Sospedra Mireia,
Weller Michael,
Budka Herbert,
Martin Roland
Publication year - 2013
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.23973
Subject(s) - natalizumab , progressive multifocal leukoencephalopathy , multiple sclerosis , jc virus , medicine , pathology , central nervous system , immune reconstitution inflammatory syndrome , granule cell , immunology , virus , dentate gyrus , antiretroviral therapy , viral load
Progressive multifocal leukoencephalopathy is the most common clinical presentation of JC virus (JCV)‐associated central nervous system (CNS) disease and has emerged as a major safety concern in multiple sclerosis patients treated with the monoclonal antibody natalizumab. Here we report clinical, radiological, and histological findings of a case of cerebellar granule cell neuronopathy (GCN), a JCV‐associated CNS disease, so far unreported amongst patients treated with natalizumab. GCN should be considered as a JCV CNS manifestation in patients with newly developed, progressive cerebellar signs under natalizumab treatment, especially in cases where cerebellar atrophy can be visualized by magnetic resonance imaging. Ann Neurol 2013;74:622–626
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom